News & Publications Press Releases Featured Press Releases April 19, 2026 EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors Press Releases April 19, 2026 Read more → Press Releases April 19, 2026 Press Releases January 8, 2026 EpiBiologics Closes $107M Series B to Advance Pipeline of Novel Bispecific Antibodies to Selectively Degrade Extracellular Protein Targets in Oncology and Immunology Press Releases January 8, 2026 Read more → Press Releases January 8, 2026 Press Releases April 28, 2025 EpiBiologics Presents First Data on c-Met Degrading Bispecific Antibody Press Releases April 28, 2025 Read more → Press Releases April 28, 2025 Press Releases November 4, 2024 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Press Releases November 4, 2024 Read more → Press Releases November 4, 2024 Press Releases April 8, 2024 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Press Releases April 8, 2024 Read more → Press Releases April 8, 2024 Press Releases July 20, 2023 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Press Releases July 20, 2023 Read more → Press Releases July 20, 2023 Press Releases March 22, 2023 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Press Releases March 22, 2023 Read more → Press Releases March 22, 2023 Publications & Presentations Featured Publications April 28, 2025 Discovery of cMET degrading bispecific antibodies (EpiTACs) for NSCLC and other cMET driven tumors Publications April 28, 2025 Read more → Publications April 28, 2025 Publications September 22, 2022 Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins Publications September 22, 2022 Read more → Publications September 22, 2022 Publications April 28, 2022 Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins Publications April 28, 2022 Read more → Publications April 28, 2022 Publications January 4, 2021 Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 Publications January 4, 2021 Read more → Publications January 4, 2021 In the News Featured In the News April 21, 2026 Biologic degraders push forward in the clinic In the News April 21, 2026 Read more → In the News April 21, 2026 In the News January 8, 2026 Google, Johnson & Johnson back protein degrader start-up In the News January 8, 2026 Read more → In the News January 8, 2026 In the News January 8, 2026 Former Genentech leaders’ protein degrader startup nets $107M In the News January 8, 2026 Read more → In the News January 8, 2026 In the News April 8, 2024 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins In the News April 8, 2024 Read more → In the News April 8, 2024 In the News March 22, 2023 At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders In the News March 22, 2023 Read more → In the News March 22, 2023
